Roche contends with loss of momentum for key medicines, currency fluctuations in Q3 but keeps growth on track
5.0
来源：
FiercePharma
发布时间：
2025-10-23 11:51
摘要：
Roche's Q3 performance was impacted by currency fluctuations and mixed sales results from key drugs. While Phesgo showed strong growth, other drugs like Ocrevus faced declines. The company remains optimistic about future growth and is actively discussing drug pricing with the U.S. government, indicating a strategic focus on navigating market challenges.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
0.5
business_impact
1.0
scientific_rigor
1.0
timeliness_innovation
1.0
investment_perspective
1.5
market_value_relevance
1.0
team_institution_background
0.0
technical_barrier_competition
0.0
关键证据
Roche's pharmaceutical division clocked sales growth of 9% at constant exchange rates.
Phesgo has grown sales an impressive 54% year-over-year.
Roche is engaged in discussions with the U.S. government regarding drug pricing negotiations.
真实性检查
否
AI评分总结
Roche's Q3 performance was impacted by currency fluctuations and mixed sales results from key drugs. While Phesgo showed strong growth, other drugs like Ocrevus faced declines. The company remains optimistic about future growth and is actively discussing drug pricing with the U.S. government, indicating a strategic focus on navigating market challenges.